CV Sciences, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
As of June 30, 2026, CV Sciences, Inc. has 213.12M shares outstanding.
| Shares Outstanding | 213.12M |
As of June 30, 2026, CV Sciences, Inc. maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.76, indicating elevated leverage, while an interest coverage ratio of -3.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.99 |
| Quick Ratio | 0.12 |
| Debt / Equity | 79.76 |
| Debt / EBITDA | -1.44 |
| Interest Coverage | -3.68 |
Over the twelve months ended June 30, 2026, CV Sciences, Inc. posted a negative return on equity (ROE) of -118.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.72, reflecting losses generated across the asset base. The company generates approximately 281,613.26 in revenue per employee across its workforce of 45.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times CV Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -118.91 |
| Return on Assets (ROA) | -27.72 |
| Revenue Per Employee | 281,613.26 |
| Employee Count | 45.25 |
| Inventory Turnover | 1.58 |
Over the twelve months ended June 30, 2026, CV Sciences, Inc. recorded 7,000.00 in income tax expense. The company reported a pretax loss of -2.00M and -2.01M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 7,000.00 |
As of the close on November 9, 2026, CV Sciences, Inc.'s stock has declined approximately 84.00% over the past 52 weeks.
| 52-Week Price Change | -84.00% |
| 50-Day Moving Average | 0.05 |
Over the twelve months ended June 30, 2026, CV Sciences, Inc. generated 12.74M in revenue and converted that into -2.01M in net income, yielding earnings per share of -0.01. EBITDA reached -872,000.00, while operating income came in at -969,000.00.
| Revenue | 12.74M |
| Gross Profit | 6.26M |
| Operating Income | -969,000.00 |
| Pretax Income | -2.00M |
| Net Income | -2.01M |
| EBITDA | -872,000.00 |
| EBIT | -969,000.00 |
| Earnings Per Share (EPS) | -0.01 |
As of June 30, 2026, CV Sciences, Inc. holds 266,000.00 in cash and equivalents against 1.25M in total debt, resulting in a net debt position of 769,000.00. Total book value stands at 1.57M, with working capital of -64,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 266,000.00 |
| Total Debt | 1.25M |
| Net Debt | 769,000.00 |
| Equity (Book Value) | 1.57M |
| Book Value Per Share | 0.01 |
| Working Capital | -64,000.00 |
CV Sciences, Inc. produced -492,000.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30,000.00 in capital expenditures, free cash flow totaled -522,000.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -492,000.00 |
| Capital Expenditures | -30,000.00 |
| Free Cash Flow | -522,000.00 |
Over the twelve months ended June 30, 2026, CV Sciences, Inc. posted a gross margin of 49.14, reflecting its pricing power and cost economics. The operating margin of -7.60 and net profit margin of -15.74 provide insight into operational efficiency.
| Gross Margin | 49.14 |
| Operating Margin | -7.60 |
| Pretax Margin | -15.69 |
| Profit Margin | -15.74 |
| EBITDA Margin | -6.84 |